drugset / Trial / NCT01164007
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease.
Timeline
- Start
- 2006-06-30
- Primary completion
- 2012-05-31
- Completion
- 2012-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Dacarbazine | Small molecule | 800 mg/m2 | Intravenous |